Close
ACHEMA MIDDLE EAST 2026
LogiPharma 2026

Drug Development

      Immutep Enters Into Clinical Trial Collaboration and Supply Agreement With Merck KGaA, Darmstadt, Germany, and Pfizer

      Clinical Trials
      Immutep Limited is pleased to announce that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and...

      Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma

      Clinical Trials
      AstraZeneca announced results from the BORA Phase III extension trial evaluating the long-term safety and efficacy of Fasenra (benralizumab) as an add-on maintenance treatment...

      New Lilly Diabetes Center of Excellence Established at the Indiana Bioscience Research Institute

      Press Statements
      Eli Lilly and Company and the Indiana Bioscience Research Institute (IBRI), in collaboration with Indiana University School of Medicine, have created the Lilly Diabetes...

      EC approves new easy-to-use, once-weekly Bydureon BCise device for patients with type-2 diabetes

      FDA Approvals
      AstraZeneca announced that the EC has approved Bydureon BCise as a new formulation within the marketing authorisation for Bydureon for the treatment of patients...

      Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab

      Clinical Trials
      Biogen and Eisai Co., Ltd. announced results from a recent analysis of the ongoing long-term extension (LTE) Phase 1b study of aducanumab, an investigational...

      Exact Sciences and Pfizer Enter into U.S. Promotion Agreement for Cologuard®

      FDA Approvals
      Exact Sciences Corp and Pfizer Inc. announced an agreement through 2021 to co-promote Cologuard, the first and only FDA-approved non-invasive stool DNA screening test...

      ViiV Healthcare reports positive 48-week results for first pivotal, phase III study for novel, long-acting, injectable HIV-treatment regimen

      Clinical Trials
      ViiV Healthcare announced positive headline results from its global, phase III ATLAS study of a long-acting, injectable two-drug regimen (2DR) for the treatment of...

      Subscribe Our Newsletter

      White Papers

      The Future of Digital Health

      Whitepapers 0
      The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

      Five Best Practices to Deliver Exceptional Multichannel Experiences

      Whitepapers 0
      A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

      The Impact and Use of Social Media in Pharmacovigilance

      Whitepapers 0
      Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...

      About us

      Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and
      comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector. . . Read More

      Resources

      Advertise

      Subscribe

      Copyright © Value Media Group 2026. All rights reserved.